3-(2-{2-[4-(tert-Butyl)phenoxy]ethoxy}-4-pyridinyl)-2-ethoxypropanoic acid | 467236-11-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(2-{2-[4-(tert-Butyl)phenoxy]ethoxy}-4-pyridinyl)-2-ethoxypropanoic acid
• 英文别名: 3-[2-[2-(4-Tert-butylphenoxy)ethoxy]pyridin-4-yl]-2-ethoxypropanoic acid
• CAS: 467236-11-9
• 化学式: C₂₂H₂₉NO₅
• 分子量: 387.476
• InChiKey: ZUSKPJHBPOKPLZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  28
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  77.9
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Carboxylic acids
  申请人：——

  公开号：US20040116708A1

  公开（公告）日：2004-06-17

  The present invention provides a novel carboxylic acid derivative, a salt thereof or a hydrate of them which is useful as an insulin sensitizer, and a medicament comprising the derivative as the effective ingredient. More specifically, it provides a carboxylic acid compound represented by the formula (I), a salt thereof or a hydrate of them. 1 In the formula, Ar represents a 6- to 14-membered aromatic ring group which may have at least one substituent; R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 and R 8 are the same as or different from each other and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a C 1-6 alkyl group or a C 1-6 alkoxy group; X represents an oxygen atom or a methylene group; Y represents a group represented by the formula (II) or (III): 2 (wherein Z represents a group represented by the formula (IV): 3 (wherein R 9 , R 10 , R 11 and R 12 are the same as or different from each other and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a C 1-6 alkyl group or a C 1-6 alkoxy group)); m is 0 or 1; and n is 0 or 1.

  本发明提供了一种新的羧酸衍生物，其盐或水合物可用作胰岛素增敏剂，并提供了一种以该衍生物为有效成分的药物。更具体地，本发明提供了一种由式(I)表示的羧酸化合物，其盐或水合物。在式中，Ar表示一个有6至14个成员的芳香环基团，该基团可以具有至少一个取代基；R1，R2，R3，R4，R5，R6，R7和R8相同或不同，每个表示氢原子，卤素原子，羟基，C1-6烷基或C1-6烷氧基；X表示氧原子或亚甲基；Y表示由式(II)或(III)表示的基团：其中Z表示由式(IV)表示的基团：其中R9，R10，R11和R12相同或不同，每个表示氢原子，卤素原子，羟基，C1-6烷基或C1-6烷氧基）；m为0或1；n为0或1。
• CARBOXYLIC ACIDS
  申请人：Eisai Co., Ltd.

  公开号：EP1375484A1

  公开（公告）日：2004-01-02

  The present invention provides a novel carboxylic acid derivative, a salt thereof or a hydrate of them which is useful as an insulin sensitizer, and a medicament comprising the derivative as the effective ingredient. More specifically, it provides a carboxylic acid compound represented by the formula (I), a salt thereof or a hydrate of them. In the formula, Ar represents a 6- to 14-membered aromatic ring group which may have at least one substituent; R1, R2, R3, R4, R5, R6, R7 and R8 are the same as or different from each other and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a C1-6 alkyl group or a C1-6 alkoxy group; X represents an oxygen atom or a methylene group; Y represents a group represented by the formula (II) or (III): (wherein Z represents a group represented by the formula (IV): (wherein R9, R10, R11 and R12 are the same as or different from each other and each represents a hydrogen atom, a halogen atom, a hydroxyl group, a C1-6 alkyl group or a C1-6 alkoxy group)); m is 0 or 1; and n is 0 or 1.

  本发明提供了一种可用作胰岛素增敏剂的新型羧酸衍生物、其盐或其水合物，以及以该衍生物为有效成分的药物。更具体地说，它提供了一种由式（I）代表的羧酸化合物、其盐或它们的水合物。 式中，Ar代表6-至14元芳香环基，该环基可具有至少一个取代基；R1、R2、R3、R4、R5、R6、R7和R8彼此相同或不同，且各自代表氢原子、卤素原子、羟基、C1-6烷基或C1-6烷氧基；X代表氧原子或亚甲基；Y代表由式(II)或(III)代表的基团： (其中 Z 代表由式（IV）代表的基团： (其中 R9、R10、R11 和 R12 彼此相同或不同，且各自代表氢原子、卤素原子、羟基、C1-6 烷基或 C1-6 烷氧基））；m 为 0 或 1；n 为 0 或 1。
• CONCOMITANT DRUG AS THERAPEUTIC AGENT FOR INFLAMMATORY BOWEL DISEASE
  申请人：Eisai Co., Ltd.

  公开号：EP1607103A1

  公开（公告）日：2005-12-21

  An object of the present invention is to provide a medicament efficacious for an inflammatory bowel disease such as ulcerative colitis or Crohn's disease. Specifically, it provides a therapeutic agent for inflammatory bowel diseases comprising active ingredient (a) consisting of at least one compound having inflammatory inhibiting activity selected from the group consisting of an aminosalicylic acid derivative, an antiinflammatory glucocorticoid, an immunosuppressive compound, an anti-TNFα antibody, a neurohypophysial hormone and an antiinfective compound, combined with active ingredient (b) consisting of at least one compound having PPARγ agonistic activity, wherein the agent is so configured that the compound (a) and the compound (b) are used simultaneously, separately or every scheduled time.

  本发明的目的是提供一种对溃疡性结肠炎或克罗恩病等炎症性肠病有效的药物。一种抗肿瘤坏死因子α抗体、一种神经生理激素和一种抗感染化合物，再加上由至少一种具有 PPARγ 激动活性的化合物组成的活性成分（b），其中制剂的配置使化合物（a）和化合物（b）可同时、分别或每次按计划使用。
• Concomitant drug as therapeutic agent for inflammatory bowel disease
  申请人：Horizoe Tatsuo

  公开号：US20060177444A1

  公开（公告）日：2006-08-10

  An object of the present invention is to provide a medicament efficacious for an inflammatory bowel disease such as ulcerative colitis or Crohn's disease. Specifically, it provides a therapeutic agent for inflammatory bowel diseases comprising active ingredient (a) consisting of at least one compound having inflammatory inhibiting activity selected from the group consisting of an aminosalicylic acid derivative, an antiinflammatory glucocorticoid, an immunosuppressive compound, an anti-TNFα antibody, a neurohypophysial hormone and an antiinfective compound, combined with active ingredient (b) consisting of at least one compound having PPARγ agonistic activity, wherein the agent is so configured that the compound (a) and the compound (b) are used simultaneously, separately or every scheduled time.

  本发明的目的是提供一种对溃疡性结肠炎或克罗恩病等炎症性肠病有效的药物。一种抗肿瘤坏死因子α抗体、一种神经生理激素和一种抗感染化合物，再加上由至少一种具有 PPARγ 激动活性的化合物组成的活性成分（b），其中制剂的配置使化合物（a）和化合物（b）可同时、分别或每次按计划使用。
• US7253178B2
  申请人：——

  公开号：US7253178B2

  公开（公告）日：2007-08-07